Identifying barriers and effective strategies to improve biomarker testing rates in non-small cell lung cancer.

e23226 Background: Biomarker testing plays a pivotal role in the management of non-small cell lung cancer (NSCLC). However, despite advancements in diagnostic technologies and clinical guidelines recommending widespread use, the adoption of biomarker testing in routine practice remains inconsistent. To address these gaps, this study summarizes the common barriers to biomarker testing in NSCLC and highlights practical solutions to increase utilization. Methods: We conducted a scoping review, guided by the JBI Manual of Evidence Synthesis and PRISMA-ScR checklist, with a comprehensive search of six databases (Medline, Embase, Cochrane CENTRAL, CINAHL, Scopus, and Web of Science) focused on NSCLC biomarker testing in U.S. and Canadian adult populations. Eligible studies addressed barriers or proposed solutions to improve testing implementation and utilization. Titles and abstracts were independently screened by two reviewers using Covidence, and data were extracted and thematically synthesized to identify common challenges and actionable strategies. Results: A total of 7,192 records were identified through database searches, of which 27 studies underwent full-text screening, and 14 studies met the inclusion criteria. Three overarching themes were identified: operational barriers, communication and knowledge gaps, and access and financial challenges. Operational barriers were the most frequently reported, with time-related constraints in 79% of studies and insufficient tissue samples in 74%. Proposed solutions included streamlining reflex testing and standardizing policy protocols and workflows (both reported in 50% of studies), leveraging advanced testing technologies (43%), and adopting comprehensive NGS panels (14%). Communication and knowledge gaps were highlighted, with knowledge deficiencies reported in 57% of studies and challenges in care coordination in 50%. Solutions to these issues included supporting education and continuous learning (71%), promoting multidisciplinary collaboration and tumor boards (57%), and leveraging data and technology (43%). Access and financial barriers were primarily driven by inadequate funding, which was reported in 71% of studies, and limited access to NGS, reported in 36%. Proposed solutions included securing funding for biomarker testing infrastructure (29%) and improving reimbursement and coverage policies (14%). Conclusions: This study highlights critical gaps in biomarker testing for NSCLC, with operational challenges and inadequate funding emerging as the most significant barriers, while being accompanied by the fewest proposed solutions. In contrast, communication and knowledge deficits were well-addressed, presenting opportunities for immediate interventions, such as enhancing education and multidisciplinary collaboration.